Predict your next investment

LivaNova company logo
Corporation
HEALTHCARE | Medical Devices & Equipment / Surgical Devices
livanova.com

See what CB Insights has to offer

Investments

12

Portfolio Exits

2

Partners & Customers

5

About LivaNova

LivaNova is a medical device company in the treatment of cardiovascular diseases. The company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.

LivaNova Headquarter Location

20 Eastbourne Terrace

London, England, W2 6LG,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing LivaNova

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find LivaNova in 1 Expert Collection, including Medical Devices.

M

Medical Devices

949 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

LivaNova Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

LivaNova Rank

Latest LivaNova News

Insights on the Cardiac Prosthetic Devices Global Market to 2027 - Featuring Abbott Vascular, Biotronik and LivaNova Among Others - ResearchAndMarkets.com

May 17, 2022

The Global Cardiac Prosthetic Devices Market size was estimated at USD 6,462.63 million in 2021, USD 7,464.09 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 15.67% to reach USD 15,481.30 million by 2027. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cardiac Prosthetic Devices Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Market Share Analysis: The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments The report answers questions such as: 1. What is the market size and forecast of the Global Cardiac Prosthetic Devices Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cardiac Prosthetic Devices Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cardiac Prosthetic Devices Market? 4. What is the competitive strategic window for opportunities in the Global Cardiac Prosthetic Devices Market? 5. What are the technology trends and regulatory frameworks in the Global Cardiac Prosthetic Devices Market? 6. What is the market share of the leading vendors in the Global Cardiac Prosthetic Devices Market? 7. What modes and strategic moves are considered suitable for entering the Global Cardiac Prosthetic Devices Market? Market Dynamics Rising health insurance coverage

LivaNova Investments

12 Investments

LivaNova has made 12 investments. Their latest investment was in Noctrix Health as part of their Series B on January 1, 2021.

CBI Logo

LivaNova Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/11/2021

Series B

Noctrix Health

$17M

Yes

4

10/25/2019

Series A

ShiraTronics

$33M

Yes

7

9/25/2018

Series B

Ceribell

$35M

Yes

3

10/30/2017

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/21/2014

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/11/2021

10/25/2019

9/25/2018

10/30/2017

10/21/2014

Round

Series B

Series A

Series B

Series A

Corporate Minority

Company

Noctrix Health

ShiraTronics

Ceribell

Subscribe to see more

Subscribe to see more

Amount

$17M

$33M

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

7

3

10

10

LivaNova Portfolio Exits

2 Portfolio Exits

LivaNova has 2 portfolio exits. Their latest portfolio exit was Respicardia on April 12, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/12/2021

Acquired

7

7/30/2018

Corporate Majority

Subscribe to see more

Subscribe to see more

10

Date

4/12/2021

7/30/2018

Exit

Acquired

Corporate Majority

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

7

10

LivaNova Acquisitions

10 Acquisitions

LivaNova acquired 10 companies. Their latest acquisition was ALung Technologies on May 05, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/5/2022

Debt

$99M

$145.12M

Acquired

2

4/4/2018

$99M

Acquired

4

2/14/2018

Series E+

$99M

$50.5M

Acquired

1

12/5/2017

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/3/2017

Other

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/5/2022

4/4/2018

2/14/2018

12/5/2017

5/3/2017

Investment Stage

Debt

Series E+

Other

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$145.12M

$50.5M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

4

1

10

10

LivaNova Partners & Customers

5 Partners and customers

LivaNova has 5 strategic partners and customers. LivaNova recently partnered with Verily Life Sciences on February 2, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

2/27/2020

Partner

United States

LivaNova, Verily collaborate on new approach for RECOVER trial

US-based medical technology firm LivaNova has entered into research collaboration with Verily , an Alphabet company , to capture measures of depression within its RECOVER clinical study .

2

9/27/2017

Partner

China

Subscribe to see more

Subscribe to see more

10

10/21/2014

Partner

United States

Subscribe to see more

Subscribe to see more

10

10/9/2014

Licensee

United States

Subscribe to see more

Subscribe to see more

10

5/28/2014

Partner

China

Subscribe to see more

Subscribe to see more

10

Date

2/27/2020

9/27/2017

10/21/2014

10/9/2014

5/28/2014

Type

Partner

Partner

Partner

Licensee

Partner

Business Partner

Country

United States

China

United States

United States

China

News Snippet

LivaNova, Verily collaborate on new approach for RECOVER trial

US-based medical technology firm LivaNova has entered into research collaboration with Verily , an Alphabet company , to capture measures of depression within its RECOVER clinical study .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

LivaNova Team

16 Team Members

LivaNova has 16 team members, including current President, Stephanie Bolton.

Name

Work History

Title

Status

Stephanie Bolton

President

Current

Paul Buckman

President

Current

Bryan Olin

Senior Vice President

Current

Andre-Michel Ballester

Chief Executive Officer

Former

Drago A Cerchiari

Sorin Group, Medtronic, and Pharmacia Corporation

Chief Executive Officer

Former

Name

Stephanie Bolton

Paul Buckman

Bryan Olin

Andre-Michel Ballester

Drago A Cerchiari

Work History

Sorin Group, Medtronic, and Pharmacia Corporation

Title

President

President

Senior Vice President

Chief Executive Officer

Chief Executive Officer

Status

Current

Current

Current

Former

Former

You May Also Like

insitro Logo
insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

Atomwise Logo
Atomwise

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

B
BIOS

BIOS is a neural engineering startup, creating the open standard hardware and software interface between the human nervous system and AI. BIOS is developing the standards, datasets, tools, and algorithms to enable a new generation of neural treatments to improve the quality of life for millions of people affected by chronic disease. Its team combines applied materials, ML, software, neuroscience in conjunction with the experience of surgeons, clinicians and patients to create a seamless and accessible user experience.

Recursion Logo
Recursion

Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease.

CVRx Logo
CVRx

CVRx (NASDAQ: CVRX) is a privately held company founded in 2001 and headquartered in Minneapolis, Minnesota. The company has developed the second-generation BAROSTIM NEO, a minimally-invasive implantable system and the only device CE Marked for the separate indications of heart failure and resistant hypertension. BAROSTIM NEO is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States. The company's BAROSTIM NEO LEGACY holds Humanitarian Device Exemption (HDE) approval from FDA, deeming it safe for use in hypertensive patients who were responders to the first-generation BAROSTIM THERAPY with Rheos Carotid Sinus Lead System.

Exscientia Logo
Exscientia

Exscientia (NASDAQ: EXAI) is an AI-driven, drug discovery, and design enterprise. Exscientia aims to use AI to discover and design better quality drugs with greater efficiency.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.